98%
921
2 minutes
20
Purpose: To evaluate postpartum hemorrhage (PPH) and IR service landscapes in Kenya using geospatial analytic mapping for outreach planning.
Materials And Methods: Geographic information system (GIS) analysis of Kenya was performed using open-source data sets. Data at the regional and county levels from 2014 to 2018 were collected to evaluate demographics and variables related to PPH and healthcare access. Population risk indices were created based on these data. Detailed multilayered GIS mapping was performed to produce visual data representations of the findings for outreach planning.
Results: From 2014 to 2018, the incidence of maternal hemorrhage in Kenya increased by 38%. Six hospitals in Kenya offer IR services that are required to treat PPH, all located in Nairobi. Relative to other counties, maternal mortality ratios (MMRs) in Nairobi were near the median, falling within standard deviations (SDs) of -0.5 to 0.5. MMRs were highest in the southeastern and northwestern regions of the country, with an increase in SD of 1.5-2.3 and 0.5-1.5, respectively. Risk index and population maps identified high-impact hospitals for IR outreach.
Conclusions: GIS analysis demonstrated disproportionate rates of maternal morbidity and mortality due to PPH in areas without IR capabilities. It proved to be a valuable tool to understand population health and can be leveraged to target global IR services strategically.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvir.2025.02.019 | DOI Listing |
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Pharmacy, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Maternity and Child Health Hospital, Fujian Medical University, #18 Daoshan Road, Fuzhou, Fujian, 350001, China.
Postpartum hemorrhage (PPH) is a life-threatening obstetric complication. We aimed to identify the drugs that associated with PPH based on the FDA Adverse Event Reporting System (FAERS) data, providing scientific evidence for targeted prevention of drug-related PPH risk factors. Data from 2004Q1 to 2025Q1 were extracted from FAERS, and disproportionality analysis was performed to identify potential drug signals.
View Article and Find Full Text PDFGynecol Obstet Fertil Senol
September 2025
Northwell Health, New Hyde Park, New York, États Unis D'Amérique; Department of Obstetrics and Gynecology South Shore University Hospital, Bay Shore, New York, États Unis D'Amérique; Department of Obstetrics and Gynecology Huntington Hospital, Huntington, New York, États Unis D'Amérique; Zucke
Am J Perinatol
September 2025
Division of Maternal and Fetal Medicine, OB/GYN and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, United States.
This study aimed to characterize the risk of adverse pregnancy outcomes among patients with congenital uterine anomalies (CUA) using electronic health record data.Retrospective cohort study utilizing the TriNetX analytics research network, including female patients aged 10 to 55 with a documented singleton and intrauterine pregnancy.A total of 561,440 patients met inclusion criteria, of whom 3,381 (0.
View Article and Find Full Text PDFBJOG
September 2025
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA.
Objective: To compare maternal and neonatal adverse outcomes between women who are English proficient (EP) and those who have limited English proficiency (LEP).
Design: Retrospective cohort study.
Setting: Single US academic medical centre with interpreter services.
Int J Obstet Anesth
September 2025
Westmead Hospital Department of Anaesthesia and Perioperative Medicine, Westmead, Australia.
Background: Maternal cardiovascular disease (CVD) is a leading cause of maternal mortality. Data on anaesthetic management in patients with CVD is limited.
Methods: This ten-year retrospective cohort study of 508 pregnancies in women with CVD, stratified by modified World Health Organization (mWHO) risk category, compared lowrisk (mWHO I-II) (n = 323) and high-risk (mWHO II to III-IV) (n = 185) groups to a control obstetric population (n = 55,153).